Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valneva Announces Positive Booster Data for COVID Vax Candidate | Contract Pharma

What are you searching for?

Sign in
Breaking News

Valneva Announces Positive Booster Data for COVID Vax Candidate

Initial results confirm inactivated, adjuvanted VLA2001 significantly boosted immunity in participants who received VLA2001 as a primary vaccination.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valneva SE announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. Initial results confirm that VLA2001 significantly boosted immunity in participants who received VLA2001 as a primary vaccination.
 
In the study, 77 of the 153 original Phase 1/2 study participants, aged 18-55 years, received a booster dose seven to eight months after completion of their primary immunization with either a low, medium or high dose of VLA2001. All participants received a single booster vaccination with VLA2001 at the same (high) dose level used in the pivotal Phase 3 “Cov-Compare” trial. IgG antibody titers (spike protein-based) were measured at the time of the booster as well as two weeks after the booster dose with 45 of the 77 boosted participants included in the final analysis.
 
A third dose of VLA2001 elicited an excellent anamnestic response, with similar antibody levels observed whether participants were initially vaccinated with a low, medium or high dose (95%). This represents a strong boosting effect, increasing levels of antibodies against the Wuhan virus 42- to 106-fold, depending on the pre-boosting levels of antibodies.
 
Antibody levels measured two weeks after the booster dose were approximately four-fold higher compared to those observed two weeks after primary immunization.
 
Valneva will also evaluate the sera from the boosted participants for cross-neutralization against Variants of Concern, including Omicron.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics